House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Gastroenterology

Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management

NICE · 2019 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

NICE CG184 covers adults with dyspepsia, gastro-oesophageal reflux symptoms or both. Its management pathway combines assessment for serious or alternative disease, lifestyle advice, Helicobacter pylori testing and symptom-directed acid suppression. Severe oesophagitis, stricture and peptic ulcer require different treatment and follow-up from uncomplicated recurrent symptoms. This summary concentrates on those clinical decisions rather than reproducing every eradication regimen or proton-pump-inhibitor dose table.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Check urgent and alternative diagnoses

  • Refer dyspepsia with significant acute gastrointestinal bleeding for specialist assessment immediately on the same day. The acute upper gastrointestinal bleeding pathway supplies the emergency management details. [1]
  • Review medicines that may cause dyspepsia, and suspend NSAIDs in people needing referral. Consider cardiac and biliary disease in the differential. Previous endoscopy can guide ongoing care only when there are no new alarm signs; use the suspected-cancer pathway for referral criteria. [1]
  • Offer healthy-eating, weight-reduction and smoking-cessation advice. Help patients identify and avoid their own symptom triggers; head-of-bed elevation and an earlier main meal may help some people. [1]

Treat uninvestigated symptoms and review long-term use

  • For uninvestigated dyspepsia, offer an empirical full-dose proton-pump inhibitor for 4 weeks and offer H pylori test-and-treat. Manage uninvestigated reflux-like symptoms through the same pathway. [1]
  • Allow a 2-week interval after stopping a PPI before H pylori breath or stool-antigen testing. For initial testing, use a urea breath test, stool antigen or locally validated laboratory serology; do not use office-based serological tests. [1]
  • When symptoms recur after initial dyspepsia care, step down to the lowest effective PPI dose and discuss as-needed treatment. Offer an H₂-receptor antagonist when response to a PPI is inadequate. [1]
  • Offer annual review for long-term dyspepsia treatment and encourage step-down or withdrawal unless another condition or medicine requires continuing therapy. Some patients can return to as-needed antacid or alginate treatment. [1]

Distinguish uncomplicated reflux from severe disease

  • For established GORD, offer a full-dose PPI for 4 or 8 weeks. If symptoms recur, use the lowest dose that controls them and discuss self-management; an H₂-receptor antagonist is an option for inadequate PPI response. [1]
  • After dilation of an oesophageal stricture, continue long-term full-dose PPI therapy. This is an exception to routine attempts to step down uncomplicated symptom treatment. [1]
  • For severe oesophagitis, offer full-dose PPI treatment for 8 weeks to promote healing. If it fails, consider a higher dose of the original PPI or another PPI, accounting for patient preferences, tolerability, comorbidities and interactions. [1]
  • Offer long-term full-dose PPI maintenance for severe oesophagitis, accounting for clinical circumstances and preferences. Persistent nonresponse warrants clinical review, consideration of a different full- or high-dose PPI and/or specialist advice. [1]

Treat ulcers and arrange appropriate follow-up

  • Offer eradication therapy for H pylori-positive peptic ulcer disease. With an NSAID-associated ulcer, stop the NSAID if possible, give full-dose PPI or H₂-receptor-antagonist therapy for 8 weeks and subsequently eradicate H pylori if present. [1]
  • For gastric ulcer with H pylori, offer repeat endoscopy 6 to 8 weeks after starting treatment, according to lesion size. For H pylori-positive gastric or duodenal ulcer, offer retesting at 6 to 8 weeks after treatment begins. [1]
  • For an H pylori-negative ulcer in someone not taking NSAIDs, offer full-dose PPI or H₂-receptor-antagonist treatment for 4 to 8 weeks. An unhealed ulcer requires review for nonadherence, malignancy, missed infection, inadvertent NSAIDs, other ulcerogenic medicines and less common causes. [1]
  • If NSAIDs remain necessary after ulcer healing, discuss harm and review the need regularly. In patients with previous ulceration who must continue an NSAID, consider a COX-2-selective agent and prescribe a PPI with either selective or standard NSAID treatment. [1]

Address persistent symptoms and eradication failure

  • For endoscopically determined functional dyspepsia, eradicate H pylori if present, then use symptom management and periodic review. If infection is excluded but symptoms persist, offer low-dose PPI or an H₂-receptor antagonist for 4 weeks. [1]
  • For continuing functional-dyspepsia symptoms, use the lowest effective PPI or H₂-receptor-antagonist dose and discuss as-needed PPI use. Avoid frequent continuous long-term antacid treatment, which offers short-term relief rather than prevention. [1]
  • Discuss adherence during H pylori eradication and seek gastroenterology advice when second-line treatment has failed. Regimen selection in this guideline accounts for penicillin allergy and prior antibiotic exposure. [1]

Discuss specialist assessment and Barrett surveillance

  • Consider specialist referral for unexplained or treatment-resistant gastro-oesophageal symptoms, consideration of surgery, or failed second-line eradication. Consider fundoplication only for confirmed acid reflux that responds to acid suppression when the patient cannot tolerate or does not wish to continue long-term medication. [1]
  • Do not routinely perform endoscopy simply to diagnose Barrett’s oesophagus, but consider it in GORD after discussing preferences and individual risk factors. For confirmed Barrett’s, consider surveillance according to dysplasia, preferences and progression risk, recognizing that harms may outweigh benefits in lower-risk disease. [1]

Limitations and use

  • This summary preserves CG184 recommendations, many dated to earlier evidence reviews; it does not represent a new guideline issued this year.
  • H pylori antibiotic combinations, dose tables and rescue regimens are not reproduced. Use current local resistance-informed prescribing advice and the complete relevant guideline.
  • Detailed cancer-referral criteria, Barrett surveillance intervals and acid-suppression dose equivalents require their respective source pathways.
  • These recommendations apply to adults; they should not be extrapolated to children or used as an acute-bleeding protocol.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management

    Selected recommendation material consulted

Original guideline

Publication details

Issuing organisation
NICE
First published
3 September 2014
Publisher’s latest update
18 October 2019
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Check urgent and alternative diagnoses
  • Treat uninvestigated symptoms and review long-term use
  • Distinguish uncomplicated reflux from severe disease
  • Treat ulcers and arrange appropriate follow-up
  • Address persistent symptoms and eradication failure
  • Discuss specialist assessment and Barrett surveillance
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House